Prostate cancer (CaP) is the most common adult male cancer in the developed world. The paucity of biomarkers to predict prostate tumor biology makes it important to identify key pathways that confer poor prognosis and guide potential targeted therapy. Using a murine forward mutagenesis screen in a Pten-null background, we identified peroxisome proliferator-activated receptor gamma (Pparg), encoding a ligand-activated transcription factor, as a promoter of metastatic CaP through activation of lipid signaling pathways, including up-regulation of lipid synthesis enzymes [fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY)]. Importantly, inhibition of PPARG suppressed tumor growth in vivo, with down-regulation of the lipid synthesis program. We show that elevated levels of PPARG strongly correlate with elevation of FASN in human CaP and that high levels of PPARG/FASN and PI3K/ pAKT pathway activation confer a poor prognosis. These data suggest that CaP patients could be stratified in terms of PPARG/FASN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARG/FASN inhibition.
PTEN | PPARG | Sleeping Beauty | prostate cancer | metastasis P rostate cancer (CaP) is now the most common male cancer and second leading cause of cancer mortality in the developed world (1) . The majority of patients are likely to die with, rather than from, CaP, making it important to identify key pathways that confer poor prognosis, thus minimizing overtreatment.
The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene (TSG), a key element of the PI3K pathway, is implicated in numerous human cancers (2) . The PI3K pathway is altered in ∼25-70% of CaP and virtually all metastatic tumors (3, 4) . Homozygous Pten deletion in the mouse prostate leads to prostatic intraepithelial neoplasia (PIN) at 12 wk of age and invasive carcinoma after 6-9 mo (5), with the long latency suggesting additional mutations are required for disease progression. Several genes cooperate with Pten loss to induce tumorigenesis in mice, including either loss of tumor suppressors such as Smad4 or Tp53 or activation of Erbb2 or Erg. However, none of these tumors fully reflect the continuum of human CaP (6) (7) (8) (9) .
Despite significant investments in clinical biobanks, nextgeneration sequencing, and other "omic" approaches, the heterogeneity and multifocal nature of CaP means that most of these technologies have not produced conclusive findings to inform on disease outcome, with large sample numbers and an extended follow-up required for statistical significance (4, 10) . As a result, multiple genes/pathways involved in CaP have been isolated, with difficulties in identifying the "driver" events from more common background "passenger" mutations. Thus, novel approaches to induce somatic mutagenesis have been developed to identify the key genes that drive metastatic CaP in vivo. One method is to use the synthetic Tc1/mariner family transposonbased Sleeping Beauty (SB) approach (11) . The SB system uses independent transgenes carrying the transposon (T2Onc3) and the enzyme transposase to initiate transpositions and thus ransom somatic mutagenesis. After integration, the transposon may disrupt the expression of TSGs in neighboring sequences or overexpress nearby full length/truncated oncogenes, using its promoter/ splice donor site. The expression of the transposase can be ubiquitous or tissue specific (using Cre-recombinase driven by tissue specific promoters). The SB model system has been used successfully to determine low-frequency somatic mutations that are drivers of tumorigenesis (12) , which is relevant in human CaP, because recent large-scale sequencing demonstrates somatic mutations are relatively rare compared with other malignancies (3).
To our knowledge, this is the first report showing acceleration of prostate tumorigenesis in a Sleeping Beauty system. We validate the feasibility of such a screen in a background of Pten Nulldriven CaP and demonstrate the oncogenic role of the lead candidate, namely peroxisome proliferator-activated receptor gamma (Pparg) in both murine and human CaP. ) mice develop CaP after a long and variable latency, providing an opportunity to characterize genes that cooperate with Pten loss to promote prostate tumorigenesis. We previously demonstrated that these Pten Null mice develop high-grade prostatic intraepithelial neoplasia (HGPIN) at 3 mo, with a slow progression to overt CaP (>10 mo), with no metastasic development up to 18 mo (6).
We hypothesized that an insertional mutagenesis approach could directly identify "driver" genes in the development of lethal CaP. Accordingly, we interbred our Pten Null model with the T2/ Onc3 transposon SB system, with a CMV enhancer/chicken β-actin (CAG) promoter to drive transposition through epithelial-specific
Significance
Using an unbiased forward mutagenesis screen, we were able to successfully identify candidate genes that drive advanced and metastatic prostate cancer (CaP). Alterations of peroxisome proliferator-activated receptor gamma (PPARG), encoding a regulator crucial of lipid metabolism, appear to play a role in the development of metastatic CaP in both humans and mice.
expression (13) )] were generated ( Fig. 1A ) and housed as previously described (11, 14) . The SB:Pten Null mice (n = 21) were monitored for tumor development, and all these mice, along with relevant controls, were available for full necropsy and tissue harvesting once the mice reached clinical end points (a combination of tumor palpability, blood in urine, and murine hunching and shortness of breath) (6) . In summary, SB:Pten Null mice exhibited significantly accelerated prostate tumorigenesis compared with the Pten Null cohort (median, 293 vs. 469 d; log-rank, P < 0.0001; Fig. 1B) , with an increase in tumor size (mean, 9.1 vs. 2.9 g; MannWhitney, P = 0.002; Fig. 1 C and D) secondary to increased proliferation as demonstrated by Ki-67 expression (n = 21 vs. 21, positive cells/high powered field (20×); Mann-Whitney, P < 0.0001; Fig. 1E and Fig. S1A ). We also observed a loss in continuity of p63 immunoreactivity, a basal cell marker, in the SB: Pten Null tumors, compared with the Pten Null controls, consistent with increased levels of invasion (Mann-Whitney, P < 0.0001; Fig.  1F and Fig. S1D ) (6) . SB:Pten Null mice had an increased frequency of metastasis to lungs (6/21 vs. 0/21; two-tailed Fisher exact, P = 0.0207) and lymph nodes (pelvic/para-aortic chain, the primary lymphatic landing site for tumor cells from the prostate; 15/21 vs. 3/21; two-tailed Fisher exact, P = 0.0004) compared with Pten Null controls ( Fig. 1G and Table 1 ).
Common insertion sites (CISs) were identified from the SB:Pten Null cohort; those CISs also found in the control cohort (SB Control ) were not analyzed further. Fifty-three genes harboring unique CIS were found to be statistically significant by chromosomal analysis, with Gaussian kernal correlation (GKC)-adjusted P < 0.05; among these genes, 10 were significant by genome-wide analysis (GKC P value adjusted across genome, P < 0.05; Dataset S1). To identify candidate genes driving aggressive/metastatic disease, we interrogated the data according to the tumor weight and the presence or absence of lung and/or lymph node infiltration (Dataset S2). Based on these criteria, we identified Pparg (isoform 1), encoding a critical regulator of lipid metabolism, as a gene of interest with dramatic synergy to Pten-mediated prostate carcinogenesis. Insertions within the Pparg gene (Pparg INT ) (n = 8 mice) were associated with larger tumors compared with tumors with non-Pparg CISs (referred to as Pparg WT ) (n = 13 mice; Mann-Whitney, P = 0.0339). In mice bearing tumors with Pparg INT , there was a significant association with the presence of metastases affecting lung or (pelvic/para-aortic) lymph nodes (twotailed Fisher's test, P = 0.0139 and 0.0046, respectively). Of interest, there were two separate significant hotspots of insertion of the transposon into the Pparg gene (Dataset S3). All of the Pparg INT were upstream of the start codon, with the transposon aligned in the forward direction (splice donor/promoter alignment), strongly suggesting that they would act to increase gene transcription (Dataset S3). Given all of the above evidence, we decided to further investigate the role of Pparg as a potential oncogene in CaP. J-L) at protein and mRNA levels. In addition, acetyl-CoA carboxylase (Acc) and ATP citrate lyase (Acly), two further related targets of PPARG, were also up-regulated at the mRNA level ( Fig. 2D) , respectively, and found an excellent correlation between the two analyses (R = 0.848; Fig. S2 ). Specifically, Pparg and the related Ppargc1b mRNA expression were up-regulated in Pparg (P = 0.0005; Dataset S5). RNA-Seq expression data also demonstrated up-regulated expression of Pparg and associated genes ( Table 2) . Consistent with enhanced cholesterol and fatty acid biosynthesis, Pparg INT tumors had enhanced Oil Red O staining, signifying increased levels of triglycerides and cholesterol esters ( Fig. 2F ; Mann-Whitney, P < 0.001). When we looked at the RNA-seq data, we observed that the Pparg INT tumors had an increased basal phenotype compared with the Pparg WT and Pten Null tumors (Fig. S3B ), in keeping with a more aggressive phenotype (15) . To rule out the effect of the transposon on genes adjacent to Pparg, we could not demonstrate any differentially expressed genes within a 200-kb flanking region around the Pparg locus in those tumors with insertions at this locus (Pparg INT ) [false discover rate (FDR)-corrected Wald test, P < 0.001; P value represents the likelihood (less than 1 in 1,000 chance) of another differentially expressed gene being found flanking a 200-kb region on either side of Pparg]. As demonstrated previously (16) 
When the whole cohort was analyzed, the Pparg INT tumors demonstrated increased levels of proliferation compared with the Pparg WT cohort (n = 8 vs. 13; Mann-Whitney, P = 0.0008; Fig. 2G ). Indeed, when we looked at the survival between the cohorts, we found that the Pparg INT subset exhibited significantly accelerated prostate tumorigenesis compared with the Pparg WT cohort (median, 231 vs. 332 d; log-rank, P < 0.0001; Fig. 2H ).
We next looked at PPARG expression in a number of human CaP cell lines (Fig. S4A ). PC3 and PC3M cells (which are PTEN deficient) demonstrated elevated levels of PPARG at both the protein and mRNA level compared with the other cell lines (Fig.  S4 A and B) . Using a highly selective and irreversible inhibitor of PPARG, GW9662 (17), we observed significant inhibition of proliferation (WST-1; Mann-Whitney, P < 0.05), colony formation (Mann-Whitney, P < 0.0001), and migration (in wound scratch assay) (ANOVA, P < 0.001) in GW9662-treated PC3 cells (Fig. S4 C-E) . To further validate data from the use of GW9662, we carried out siRNA-mediated gene silencing of PPARG in PC3, PC3M, and DU145 cells. We confirmed that PPARG expression was reduced at the protein and mRNA (by >70%) level (Fig. 3A and Fig. S4 F and G) . Supporting data from GW9662 treatment, siRNA knockdown of PPARG in PC3, PC3M, and DU145 cells significantly suppressed cell proliferation (Mann-Whitney, P < 0.01; Fig. 3B and Fig. S4H ) and migration at 24 h (ANOVA, P < 0.001; Fig. 3C and Fig. S4 I and J) . In addition, colony-forming assays demonstrated a reduction in the number of colonies with siRNA treatment of PC3 cells (MannWhitney, P < 0.0001; (Fig. S4 K and L) . We next investigated the role that down-regulation of PPARG activity had on its transcriptional activity using an ELISA. We found that down-regulation of PPARG using the GW9662 compound reduced the transcriptional activity of PC3 and PC3M cells in a statistically significant fashion (Fig. 3D) .
To confirm that PPARG was responsible for the observed phenotype, we next transiently overexpressed PPARG in DU145 cells, which have low basal levels of PPARG (Fig. S4 A and B) . This up-regulation of PPARG resulted in an increase in levels of FASN (Fig. S4M) , and enhanced proliferation (Mann-Whitney, P < 0.001) and migration (at 18 h; ANOVA, P < 0.01) compared with the empty vector controls (Fig. S4 N and O) .
The in vivo effects of GW9662 were tested in a PC3 orthograft model, whereby ∼7 million PC3 cells were injected into the anterior prostate of individual mice. GW9662 treatment was started 2 wk later when the tumors became palpable. Mice were then culled after 4 wk of treatment. There was a trend (nonsignificant) toward inhibition of tumor growth with GW9662 treatment compared with vehicle control cohort (Fig. S5 A-C ). There were, however, statistically significant reductions in Ki-67 (Fig. 3 E-G; P < 0.0001) and FASN expression (Fig. 3 H-J and Fig. S5D ; P = 0.0004). Importantly, there was a significant reduction in the number of positive Pan-CK cells observed in the pelvic/para-aortic lymph nodes of the GW9662 treated cohort, suggesting a substantial reduction in the metastatic burden (P < 0.0001; Fig. 3 K-M).
PPARG Expression Level Correlates with PTEN Loss and FASN Expression
in Human CaP and Confers a Poor Prognosis. Using our previously published tissue microarray (TMA; n = 229) to investigate the expression of PPARG in CaP (6), we found that the expression of both PPARG and FASN was up-regulated in CaP (primary Gleason grades 3-5) compared with the benign prostatic hyperplasia (BPH) control cohort (Fig. 4 A-F) . In terms of coexpression, we were able to demonstrate significant correlations between up-regulated expression of PPARG with low PTEN expression (below the median; Pearson correlation coefficient, r = 0.247, P < 0.0001) and up-regulation of pAKT (r = 0.291, P < 0.0001; Table 3 strongest correlation between up-regulation of both PPARG and FASN levels (Pearson correlation coefficient, r = 0.415, P < 0.0001; Table 3 ). Disease-specific survival (DSS) in this cohort (n = 98/199 patients died of CaP) demonstrated no individual association with up-regulation of PPARG, FASN, and pAKT or low PTEN status when analyzed in isolation. In addition, up-regulated PPARG or FASN on a high PTEN or low pAKT background made no difference to DSS (Fig. S6 E-H) . However, patients who had up-regulated PPARG expression with low PTEN had a marked reduction in DSS compared with those patients with only low PPARG (median, 2.05 vs. 7.05 y; P = 0.0015; Fig. 4G ). Similarly, patients with up-regulated PPARG expression with high pAKT had a reduced DSS (median, 2.09 vs. 6.32 y; P = 0.0198; Fig. 4I ). In keeping with a functional link between PPARG and FASN, up-regulated FASN expression on both a low PTEN and high pAKT background was also associated with shorter DSS (median, 1.91 vs. 7.49 y; P = 0.0006, and median, 2.045 vs. 6.2 y; P = 0.0047, respectively; Fig. 4 H and J) .
Discussion
Prostate cancer remains a significant health problem worldwide, being the most common solid organ cancer among men and second only to lung cancer as a cause of cancer-related death in males. CaP in humans is thought to arise via an accumulation of mutations in tumor related genes transforming benign prostatic epithelium to HGPIN that progresses to overt disease and subsequent metastasis. In this study, patients with CaP that have low levels of PTEN (or activation of pAKT) and accompanying PPARG (or FASN) overexpression in their prostates appear to have a poorer prognosis. In isolation, neither factor alters survival of CaP patients. In the mouse, Pparg activating mutations, on a background of Pten deletion, accelerates prostate carcinogenesis to result in metastatic disease, with associated up-regulated expression of proteins involved in lipid metabolic pathways. Importantly, treatment of a PC3 orthograft model with a PPARG inhibitor appears to negate the effects of activated PPARG, restoring the PTEN loss-induced phenotype. Additional validation could include use of a transgenic Pten null model that has prostatespecific Pparg overexpression.
A recent sequencing study of 218 CaPs found inactivating mutations in PTEN in 4% of primary and 42% of metastatic tumors (3) . When the authors examined the entire PI3K pathway (including loss of the tumor suppressors PHLPP and INPP4B, as well as activation of the PI3KCA gene itself), the PI3K pathway was deregulated in 42% of primary tumors and in all metastases (3). Another recent multi-institutional sequencing study revealed somatic alteration in 49% (73/150) of the metastatic castrate-resistant prostate cancer cases (4). Therefore, within human CaP, deregulation of PI3K signaling appears essential for prostate cancer progression. Certainly in the murine context, it appears, from our data, to be vital as a "driver" mutation to instigate tumorigenesis.
PPARG is a ligand-activated transcription factor, belonging to the nuclear hormone receptor family (18) . On activation by a variety of natural/synthetic PPARG agonists, heterodimerization with the retinoic acid receptor (RXR) occurs, followed by nuclear translocation of the complex where it initiates target gene transcription through binding to the peroxisome proliferator response element (PPRE) (18) . PPARG has been implicated in adipocyte differentiation, functioning as a critical link between lipid and carbohydrate metabolism (19) . The role of PPARG1 (isoform 1) role in cancer biology is poorly characterized, with both tumor suppressing and oncogenic effects reported (20, 21) . PPARG2 (isoform 2) is expressed at negligible levels in murine tumors and human cell lines, at both the mRNA and protein levels (18) .
CaP cell lines and clinical specimens exhibit elevated levels of PPARG (22, 23) . Paradoxically, it appears that PPARG activation using synthetic ligands (at high concentrations) suppresses in vitro growth in LNCaP, DU145, and PC3 prostate cancer cell lines and in vivo s.c. PC3 growth (20, 24, 25) . However, recent evidence suggests these agonists may act via a PPARGindependent manner to induce cell cycle arrest and apoptosis in CaP (24) .
Recent work demonstrates that loss of Pparg coactivator 1α (Pgc1α) is protective in chemical-induced colon and liver carcinogenesis in mice, with Pgc1α activation inducing expression of a gene profile (Acly, Acc, and Fasn) that promotes conversion of glucose into fatty acids to support tumorigenesis (26) . In our RNA-Seq data we demonstrated enrichment of Pparg-coactivator 1β. It is well known that lipogenesis is a crucial factor for prostate cancer development and progression, predominantly through the enzymes ACLY, ACC, and FASN (27) .
Our data are consistent with data on clinical CaP from cBio portal (www.cbioportal.org): PPARG gene amplification was found in 26% advanced CaP specimens. Interestingly, the enzyme 15-lipoxygenase-2 (15-LOX-2), which synthesizes 15-S-hydroxyeicosatetraenoic acid (15-S-HETE), an endogenous ligand of PPARG (28), was found up-regulated in a further 17% (Fig. S7) . In total, one half of all sequenced tumors demonstrate up-regulation of one or more of the lipid synthesis genes (FASN, ACC, ACLY). Confirming our TMA data, if one or more of these genes is altered, there is a reduction in DSS [Memorial Sloan Kettering Cancer Centre (MSKCC) cohort; P = 0.0181; Fig. S7 ].
In summary, we demonstrate that PPARG up-regulation in a PTEN-null background will cause more aggressive tumorigenesis compared with PTEN-null tumors, with changes in expression of enzymes involved in lipid synthesis pathways. Knockdown and inhibition of PPARG appears to reduce tumorgenesis both in an in vitro and in vivo setting, whereas overexpression of PPARG results in a more aggressive phenotype. Collectively, our data suggest the possibility for targeted therapies using PPARG/ FASN inhibitors in this CaP patient subgroup (low PTEN/high pAKT expression).
In addition, to our knowledge, we are the first to demonstrate the strength of the SB transposon model system in successfully determining low-frequency somatic mutations that may drive prostate tumorigenesis. We envisage that this type of screen could provide a useful platform to identify putative driver events in both castration-and chemotherapy-resistant CaP.
Materials and Methods
Mouse Strains. All murine experiments were approved by the Animal Welfare and Ethical Review Board (AWERB) at the University of Glasgow. Further information is given in SI Materials and Methods.
CIS Analysis. Information is given in SI Materials and Methods.
RNA Extraction. Total RNA was extracted from frozen mouse prostate tumors from Pten Null mice and SB:Pten Null mice with (Pparg WT ) and without (Pparg INT ) Pparg insertions and from human CaP cell lines using the RNeasy Mini Kit (QIAgen; 74104) according to the manufacturer's instructions. RNA quantity and quality were evaluated by spectrophotometry using the NanoDrop 2000 spectrophotometer (Thermo Scientific) and 2100 Bioanalyzer (Agilent) RNA electropherograms, with calculation of RNA integrity number (RIN). 
